Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Shun Tsuyuki"'
Autor:
Takahiro Ando, Sho Shimada, Jun Sugihara, Koji Takayama, Masayoshi Kobayashi, Yoshihiro Miyashita, Tatsuya Ito, Kaori Okayasu, Shun Tsuyuki, Takehiko Ohba, Masafumi Doi, Hiroaki Saito, Toshihide Fujie, Tomoshige Chiaki, Atsushi Nakagawa, Tatsuhiko Anzai, Kunihiko Takahashi, Sho Shibata, Tomoya Tateishi, Yasunari Miyazaki
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 24, p 7640 (2023)
The post-acute sequelae of SARS-CoV-2 (PASC) pose a threat to patients’ health-related quality of life (HRQOL). Here, the impact of COVID-19 on HRQOL and the clinical factors associated with impaired HRQOL were examined. Discharged COVID-19 patient
Externí odkaz:
https://doaj.org/article/c9e266784e48435c9fb48c045a59f17f
Autor:
Takahiro Ando, Sho Shimada, Jun Sugihara, Koji Takayama, Masayoshi Kobayashi, Yoshihiro Miyashita, Tatsuya Ito, Kaori Okayasu, Shun Tsuyuki, Takehiko Ohba, Masafumi Doi, Hiroaki Saito, Toshihide Fujie, Tomoshige Chiaki, Atsushi Nakagawa, Tatsuhiko Anzai, Kunihiko Takahashi, Sho Shibata, Tomoya Tateishi, Yasunari Miyazaki
Long-term sequelae of COVID-19 can affect health-related quality of life (HRQOL). We examined the long-term impact of COVID-19 on HRQOL and elucidated factors associated with low HRQOL. Discharged COVID-19 patients were assessed at 3 and 6 months aft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70f993bb2675c7382b484473ba3b64dd
https://doi.org/10.21203/rs.3.rs-2937705/v1
https://doi.org/10.21203/rs.3.rs-2937705/v1
Autor:
Kazuhiro Shimaya, Yoshikazu Tsukada, Tsukasa Okamoto, Kazuhito Saitou, Tatsuo Kawahara, Ichirou Natsume, Takaaki Yamashita, Shun Tsuyuki, Masayoshi Kobayashi, Hiroaki Saito, Yasuto Jin, Hiroyuki Sakashita, Akifumi Mochizuki, Yuri Tasaka, Yoshihiro Miyashita, Takayuki Honda, Tomoshige Chiaki, Reiko Taki, Toshiharu Tsutsui, Rie Sakakibara, Yasunari Miyazaki, Haruna Watabe, Naoki Nishiyama, Takahiro Mitsumura
Publikováno v:
Lung Cancer. 155:120-126
The efficacy of immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) patients with pre-existing interstitial lung disease (ILD) is unclear.Retrospective medical data from advanced or recurrent NSCLC patients who were treated with